TBI-166

Synonym(s): Pyrifazimine

Class: Riminophenazine

Details of activity:	Active against Mycobacterium sp.
Description:	Synthetic compound derived from optimization of riminophenazine analogues
Institute where first reported:	Institute of Materia Medica of the Chinese Academy of Medical Sciences
Year first mentioned:	2012
Highest developmental phase:	Phase 2 (NCT04670120)
Development status:	Active (as of 2023)

Chemical structure(s):
Canonical SMILES:	COC1CCC(CC1)N=C2C=C3C(=NC4=C(C=CC=C4)N3C5=CC=C(C=C5)OC(F)(F)F)C=C2NC6=CC=CN=C6OC
Isomeric SMILES:	COC1CCC(CC1)N=C2C=C3C(=NC4=CC=CC=C4N3C5=CC=C(C=C5)OC(F)(F)F)C=C2NC6=C(N=CC=C6)OC
InChI:	InChI=1S/C32H30F3N5O3/c1-41-22-13-9-20(10-14-22)37-27-19-30-28(18-26(27)39-25-7-5-17-36-31(25)42-2)38-24-6-3-4-8-29(24)40(30)21-11-15-23(16-12-21)43-32(33,34)35/h3-8,11-12,15-20,22,39H,9-10,13-14H2,1-2H3
InChI Key:	GUSGYHIQYWRCQO-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/53377576

External links:
Guide to Pharmacology:	TBI-166
Main Source:	https://journals.asm.org/doi/10.1128/aac.00658-22
Citation:	https://journals.asm.org/doi/10.1128/AAC.00699-11
Patent:	WO2012003190A1